TY - JOUR
T1 - Deep learning-based classifier for carcinoma of unknown primary using methylation quantitative trait loci
AU - Walker, Adam
AU - Fang, Camila S.
AU - Schroff, Chanel
AU - Serrano, Jonathan
AU - Vasudevaraja, Varshini
AU - Yang, Yiying
AU - Belakhoua, Sarra
AU - Faustin, Arline
AU - William, Christopher M.
AU - Zagzag, David
AU - Chiang, Sarah
AU - Acosta, Andres Martin
AU - Movahed-Ezazi, Misha
AU - Park, Kyung
AU - Moreira, Andre L.
AU - Darvishian, Farbod
AU - Galbraith, Kristyn
AU - Snuderl, Matija
N1 - Publisher Copyright:
© The Author(s) 2024. Published by Oxford University Press on behalf of American Association of Neuropathologists, Inc.
PY - 2025/2/1
Y1 - 2025/2/1
N2 - Cancer of unknown primary (CUP) constitutes between 2% and 5% of human malignancies and is among the most common causes of cancer death in the United States. Brain metastases are often the first clinical presentation of CUP; despite extensive pathological and imaging studies, 20%-45% of CUP are never assigned a primary site. DNA methylation array profiling is a reliable method for tumor classification but tumor-type-specific classifier development requires many reference samples. This is difficult to accomplish for CUP as many cases are never assigned a specific diagnosis. Recent studies identified subsets of methylation quantitative trait loci (mQTLs) unique to specific organs, which could help increase classifier accuracy while requiring fewer samples. We performed a retrospective genome-wide methylation analysis of 759 carcinoma samples from formalin-fixed paraffin-embedded tissue samples using Illumina EPIC array. Utilizing mQTL specific for breast, lung, ovarian/gynecologic, colon, kidney, or testis (BLOCKT) (185k total probes), we developed a deep learning-based methylation classifier that achieved 93.12% average accuracy and 93.04% average F1-score across a 10-fold validation for BLOCKT organs. Our findings indicate that our organ-based DNA methylation classifier can assist pathologists in identifying the site of origin, providing oncologists insight on a diagnosis to administer appropriate therapy, improving patient outcomes.
AB - Cancer of unknown primary (CUP) constitutes between 2% and 5% of human malignancies and is among the most common causes of cancer death in the United States. Brain metastases are often the first clinical presentation of CUP; despite extensive pathological and imaging studies, 20%-45% of CUP are never assigned a primary site. DNA methylation array profiling is a reliable method for tumor classification but tumor-type-specific classifier development requires many reference samples. This is difficult to accomplish for CUP as many cases are never assigned a specific diagnosis. Recent studies identified subsets of methylation quantitative trait loci (mQTLs) unique to specific organs, which could help increase classifier accuracy while requiring fewer samples. We performed a retrospective genome-wide methylation analysis of 759 carcinoma samples from formalin-fixed paraffin-embedded tissue samples using Illumina EPIC array. Utilizing mQTL specific for breast, lung, ovarian/gynecologic, colon, kidney, or testis (BLOCKT) (185k total probes), we developed a deep learning-based methylation classifier that achieved 93.12% average accuracy and 93.04% average F1-score across a 10-fold validation for BLOCKT organs. Our findings indicate that our organ-based DNA methylation classifier can assist pathologists in identifying the site of origin, providing oncologists insight on a diagnosis to administer appropriate therapy, improving patient outcomes.
KW - DNA methylation
KW - EPIC array
KW - cancer of unknown primary
KW - classifier
KW - deep learning
KW - metastasis
KW - molecular pathology
UR - http://www.scopus.com/inward/record.url?scp=85215949625&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85215949625&partnerID=8YFLogxK
U2 - 10.1093/jnen/nlae123
DO - 10.1093/jnen/nlae123
M3 - Article
C2 - 39607989
AN - SCOPUS:85215949625
SN - 0022-3069
VL - 84
SP - 147
EP - 154
JO - Journal of Neuropathology and Experimental Neurology
JF - Journal of Neuropathology and Experimental Neurology
IS - 2
ER -